593249-20-8 Usage
Uses
Used in Pharmaceutical Industry:
1-(4-Amino-2-fluorophenyl)-3-pyrrolidinol is used as a building block for the synthesis of various pharmaceuticals and organic compounds. Its unique structure and properties make it valuable for drug development and research, contributing to the creation of novel therapeutic agents.
Used in Fluorinated Pharmaceutical Development:
The presence of a fluorine atom in 1-(4-Amino-2-fluorophenyl)-3-pyrrolidinol makes it an important compound in the development of fluorinated pharmaceuticals. These fluorinated compounds are known for their enhanced bioavailability and metabolic stability, which can improve the efficacy and safety of drugs in the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 593249-20-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,9,3,2,4 and 9 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 593249-20:
(8*5)+(7*9)+(6*3)+(5*2)+(4*4)+(3*9)+(2*2)+(1*0)=178
178 % 10 = 8
So 593249-20-8 is a valid CAS Registry Number.
593249-20-8Relevant academic research and scientific papers
THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY
-
Page/Page column 32, (2008/06/13)
To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, R 1 is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R 2 is methyl; R 3 is a hydrogen atom; and R 4 is a group: -CONR 5 R 6 (in which any one of R 5 and R 6 is a hydrogen atom)].
3-(4-AMINOPHENYL) THIENOPYRIMID-4-ONE DERIVATIVES AS MCH R1 ANTAGONISTS FOR THE TREATMENT OF OBESITY, DIABETES, DEPRESSION AND ANXIETY
-
Page/Page column 41, (2010/02/11)
This invention relates to novel arylamines which are antagonists of the melanin-concentrating hormone receptor 1 (MCH R1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in medicines for the treatment
